NEWS

WIRES

OTHER

Allezoe Medical Holdings (ALZM) Completes Exclusive Licensing Deal for HPV Diagnostic Technology

Allezoe Medical Holdings, Inc. (OTCBB:ALZM) announces that it has acquired the exclusive license to develop and market patent pending, advanced "see and treat" diagnostic technology for Human papillomavirus (HPV), the world's leading sexually transmitted infection (STI). An exclusive license has been signed by SureScreen Medical, Inc., a wholly-owned subsidiary of Allezoe, and AVM Corp., which recently acquired the technology and the pending patent application from its developer, Aequorea Vision Medical, Inc. Under the terms of the license, SureScreen will develop and market products worldwide using the technology in return for a fixed royalty to AVM, commencing on sales of products using the technology.

As a result of the license, Allezoe now holds the exclusive worldwide rights to this groundbreaking "see and treat" technology which will allow healthcare providers to identify cell damage from HPV instantaneously, bypassing the long lab wait times, fees and additional patient discomfort found in existing HPV diagnostic methods on the market, including the Pap smear.

With this license and the global marketing and distribution strategy it is developing, Allezoe will be positioned to enter its market. In the United States alone, there is a $6 billion annual diagnosis and treatment market for HPV, and the market is increasing under growing national attention to the virus. Recently, the Centers for Disease Control and Prevention has recommended the HPV vaccine be used for men as well. Allezoe's technology is a crucial counterpart to the vaccine, identifying any preexisting damage before vaccine administration; importantly, it also offers an important alternative for those who avoid the vaccine due to controversial side effects.

Infecting 233 million women worldwide, the virus is the leading cause of cervical cancer in women, which often results in death. HPV is known to cause a growing number of cancers and lesions in both genders, including cervical, neck, and throat cancer. More recently, HPV is being researched as a possible cause of heart disease. Allezoe's technology is a one-stop HPV solution for patients and their providers. Allezoe's HPV technology will be welcome in the United States, where healthcare costs are a growing concern. It has important implications for healthcare abroad and in poorer nations where patients do not have the luxury of making repeated visits to a clinic or waiting several days for a Pap smear report from a distant laboratory.

Allezoe CEO Michael Gelmon says, "This is not a virus we have the luxury of ignoring, when hundreds of millions of people around the world are affected and are further spreading the virus. Our new licensed technology offers the combination of accuracy plus efficiency. This is a large market that we are looking forward to penetrating, and we have a strategy in place so we can hit the ground running."

About Allezoe Medical Holdings

Allezoe Medical Holdings, Inc. (OTCBB:ALZM) is a holding company focused on acquiring the most high quality and in-demand medical products, solutions and services. Whether through diagnosis, treatment, or medical research itself, Allezoe is interested in companies that are making a striking difference in the healthcare system through technology and treatments for health issues that affect large populations. For more information, please visit www.allezoe.com.

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company's most recently filed form 10-K and Form 10-Q reports. The Company assumes no obligation to update the statements contained in this release except as required by applicable securities disclosure rules. The Company's SEC filings are available at http://www.sec.gov.